Omnicell, Inc. (NASDAQ:OMCL) EVP Scott Peter Seidelmann sold 1,300 shares of Omnicell stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $75.17, for a total transaction of $97,721.00. Following the sale, the executive vice president now directly owns 26,333 shares of the company’s stock, valued at $1,979,451.61. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Scott Peter Seidelmann also recently made the following trade(s):

  • On Monday, June 17th, Scott Peter Seidelmann sold 1,750 shares of Omnicell stock. The stock was sold at an average price of $81.55, for a total transaction of $142,712.50.

Omnicell stock traded up $0.90 during mid-day trading on Friday, hitting $73.69. The company’s stock had a trading volume of 6,909 shares, compared to its average volume of 243,395. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.03 and a quick ratio of 1.54. The stock has a market cap of $3.00 billion, a price-to-earnings ratio of 48.18, a price-to-earnings-growth ratio of 2.35 and a beta of 1.13. The business has a 50 day moving average price of $71.70 and a 200-day moving average price of $78.73. Omnicell, Inc. has a 12 month low of $56.96 and a 12 month high of $92.59.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.04. The business had revenue of $217.40 million during the quarter, compared to the consensus estimate of $214.13 million. Omnicell had a net margin of 5.70% and a return on equity of 11.85%. The firm’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.46 earnings per share. On average, equities research analysts expect that Omnicell, Inc. will post 2.05 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Omnicell by 5.7% during the second quarter. BlackRock Inc. now owns 6,413,649 shares of the company’s stock valued at $551,764,000 after acquiring an additional 344,744 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Omnicell by 4.6% during the second quarter. Vanguard Group Inc. now owns 4,223,552 shares of the company’s stock valued at $363,352,000 after acquiring an additional 186,781 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in shares of Omnicell by 1.9% during the second quarter. Conestoga Capital Advisors LLC now owns 1,575,661 shares of the company’s stock valued at $135,554,000 after buying an additional 29,493 shares during the period. Invesco Ltd. increased its position in shares of Omnicell by 79.8% during the second quarter. Invesco Ltd. now owns 779,632 shares of the company’s stock valued at $67,072,000 after buying an additional 346,029 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Omnicell by 1.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 682,598 shares of the company’s stock valued at $58,724,000 after buying an additional 10,042 shares during the period. 99.57% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have recently issued reports on OMCL. Craig Hallum raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 price objective for the company in a report on Friday, July 26th. Zacks Investment Research raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 price objective for the company in a report on Monday, July 29th. BidaskClub downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a report on Thursday, June 27th. Finally, ValuEngine downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $79.11.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Further Reading: How Investors Use a Balance Sheet

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.